Cas:944718-32-5 6-bromo-1-methylbenzotriazole manufacturer & supplier

Chemical Name:6-bromo-1-methylbenzotriazole

CAS.NO:944718-32-5

Synonyms:6-bromo-1-methyl-1H-benzo[d][1,2,3]triazole

Molecular Formula:C₇H₆BrN₃

Molecular Weight:212.04700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:268ºC

Density:1.78

Index of Refraction:1.714

PSA:30.71000

Exact Mass:210.97500

LogP:1.73080

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6-bromo-1-methyl-1H-benzo[d][1,2,3]triazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-bromo-1-methyl-1H-benzo[d][1,2,3]triazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-bromo-1-methyl-1H-benzo[d][1,2,3]triazole Use and application,6-bromo-1-methyl-1H-benzo[d][1,2,3]triazole technical grade,usp/ep/jp grade.

Related News: I believe they came to the right decision on behalf of the American public, Sandrock said in an interview. 6-bromo-1-methylbenzotriazole manufacturer FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus. 6-bromo-1-methylbenzotriazole supplier The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. 6-bromo-1-methylbenzotriazole vendor On Friday, the US Association of Flight Attendants — which represents 50,000 flight attendants across 20 airlines — called on the government to work with airlines to discontinue all travel to China until the spread of coronavirus is contained. 6-bromo-1-methylbenzotriazole factory The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting.